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Abstract
Background and purpose Breast carcinoma is the most
common cancer in female patients with a propensity for
recurrence and metastases. The accuracy of ultrasound
(US), computed tomography (CT), magnetic resonance
imaging (MRI), scintimammography (SMM) and positron
emission tomography (PET) in diagnosing the recurrent
and/or breast cancer has never been systematically asses-
sed, and present systematic review was aimed at this issue.
Methods MEDLINE and EMBASE were searched for
articles dealt with detection of recurrent and/or metastatic
breast cancer by US, CT, MRI, SMM or PET whether
interpreted with or without the use of CT. Histopathologic
analysis and/or close clinical and imaging follow-up for at
least 6 months were used as golden reference. We extracted
data to calculate sensitivity, speciﬁcity, summary receiver
operating characteristic curves and area under the curve
and to test for heterogeneity.
Result In 42 included studies, US and MRI had highest
pooled speciﬁcity (0.962 and 0.929, respectively); MRI and
PET had highest pooled sensitivity (0.9500 and 0.9530,
respectively). The AUC of US, CT, MRI, SMM and PET
was 0.9251, 0.8596, 0.9718, 0.9386 and 0.9604, respec-
tively. Results of pairwise comparison between each
modality demonstrated that AUC of MRI and PET was
higher than that of US or CT, p\0.05. No statistical
signiﬁcance was found between MRI and PET. There was
heterogeneity among studies and evidence of publication
bias.
Conclusion In conclusion, MRI seemed to be a more
useful supplement to current surveillance techniques to
assess patients with suspected recurrent and/or metastatic
breast cancer. If MRI shows an indeterminate or benign
lesion or MRI was not applicable, FDG-PET could be
performed in addition.
Keywords Recurrent and/or metastatic breast cancer 
US  CT  MRI  SMM  PET  Meta-analysis
Introduction
Breast carcinoma is the most common cancer in women in
Western Europe and the United States with an incidence
highest in the 40–55 age range, and its prevalence is still
on the rise (Parker et al. 1997; von Fournier et al. 1993).
It accounts for 40,000 and 14,000 deaths yearly in the US
and UK, respectively, and that makes it the second cause of
cancer death in women in those countries (Parker et al.
1997; American Cancer Society 2002; Cancer Research
Campaign 1996). Despite major progress in surgical
treatment, radiotherapy, and adjuvant chemotherapy pro-
tocols, tumor recurrence and metastasis have remained as a
major problem in breast cancer management (Yilmaz et al.
2007). Approximately, the risk for patient of breast cancer
to develop recurrence is 7–30% and to suffer distant
metastases is 45–90% at some time within the course of
their disease (Bongers et al. 2004). The survival of women
suffering form recurrence and metastasis is strikingly
different: Women with a local recurrence have a 21–36%
5-year relative survival rate (Bongers et al. 2004), while
women with distant metastatic disease have a 25% 5-year
relative survival rate (Isasi et al. 2005). Early detection and
accurate restaging of recurrent breast cancer are important
to deﬁne appropriate therapeutic strategies and increase the
chances of a cure (Schmidt et al. 2008; Radan et al. 2006;
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most important prognostic factors in women with breast
cancer which changes the intention of therapy from cura-
tive to palliative (Landheer et al. 2005). Thus, it is critical
to detect recurrence and distant metastases in the follow-up
of women with breast cancer.
According to the recommendations of the American
Society of Clinical Oncology (ASCO) 2006 update of the
breast cancer follow-up and management guidelines in
the adjuvant setting, physical examination and mam-
mography should be used routinely in the breast cancer
surveillance. Additional imaging methods, such as chest
X-ray, bone scans, liver ultrasound (US), computed
tomography (CT) scans, positron emission tomography
with
18F-ﬂuoro-deoxy-glucose (FDG-PET) scans and
breast magnetic resonance imaging (MRI), are not rec-
ommended (Khatcheressian et al. 2006). But physical
examination and mammography have their limitations,
especially for lesions situated deep in the muscle
layer, some distance away from the scar or in the axilla
(Rissanen et al. 1993). Furthermore, the surgery and
radiotherapy could also induce deleterious changes in
breast tissue (Stomper et al. 1987;O r e le ta l .1992;
Dershaw et al. 1992). In such cases, the reliability of the
diagnosis might be complemented by the use of the recent
conventional anatomic imaging modalities such as US,
CT, MRI, scintimammography (SMM) or the whole-body
imaging modality FDG-PET, which provides information
about the metabolic activity of tumors.
Although extensive researches have been performed
with regard to US, CT, MRI, SMM and FDG-PET for the
detection of recurrent and metastatic breast cancer, no
comprehensive comparison has yet been conducted
among all the non-invasive diagnostic tools. Isasi et al.
(2005) performed a meta-analysis to assess FDG-PET for
the evaluation of breast cancer recurrences and metasta-
ses; however, it did not assess other important non-
invasive methods—US, CT, MRI, SMM which are widely
used both in surveillance and follow-up. Thus, our study
aims to perform a comprehensive systematic review to
obtain the overall diagnostic performance of US, CT,
MRI, SMM and FDG-PET for the detection of recurrent
and metastatic breast cancer on a per-patient and a per-
lesion basis, which, to our knowledge, had not previously
been studied.
Materials and methods
Literature search
A computer literature search as a comprehensive search
(Deville ´ et al. 2000) of abstracts about studies in human
subjects from January 1995 to August 2008 through
MEDLINE and EMBASE databases was performed to
identify articles about the diagnostic performance of US,
CT, MRI, SMM and PET (interpreted with or without the
use of CT) for the detection of recurrent and metastatic
breast cancer. The following keywords were used: (‘‘US’’
OR ‘‘ultrasound’’ OR ‘‘CT’’ OR ‘‘computed tomography’’
OR ‘‘MRI’’ OR ‘‘magnetic resonance imaging’’ OR ‘‘scin-
timammography’’ OR ‘‘SMM’’ OR ‘‘PET’’ OR ‘‘positron
emission tomography’’ OR ‘‘FDG’’ OR ‘‘ﬂuorodeoxyglu-
cose’’) AND (‘‘breast carcinoma’’ OR ‘‘breast cancer’’ OR
‘‘carcinoma of breast’’ OR ‘‘breast neoplasm’’) AND
(‘‘sensitivity’’ OR ‘‘speciﬁcity’’ OR ‘‘false negative’’ OR
‘‘false positive’’ OR ‘‘diagnosis’’ OR ‘‘detection’’ OR
‘‘accuracy’’). The China bio-medicine databases were used
for Chinese articles with the following keywords: (‘‘US’’
OR ‘‘CT’’ OR ‘‘MRI’’ OR ‘‘scintimammography’’ OR
‘‘SMM’’ OR ‘‘PET’’ OR ‘‘FDG’’) AND ‘‘breast carcinoma’’
(in Chinese). Other databases such as Cochrane Library,
Cancerlit, and China National Knowledge Infrastructure
database were also searched for relevant articles. Carefully
extensive cross-checking of the reference lists of all
retrieved articles was done to supplement the list of articles.
Selection of studies
The inclusion criteria were as follows: (1) full reports
published in English or Chinese, (2) all articles in the
published literature, (3) both retrospective and prospective
articles, (4) articles dealt with the performance of US, CT,
MRI, SMM and PET (alone or in combination, but not in
sequence) in recurrent and metastatic breast carcinoma.
(5) Only articles conﬁrmed the diagnosis with the reference
standard as histopathologic analysis and/or close clinical
and imaging follow-up for at least 6 months. (6) Only
articles that present sufﬁcient data to calculate the true-
positive (TP) and false-negative (FN) values were inclu-
ded. (7) At least 10 patients were included in the article.
(8) When data or subsets of data were presented in more
than one article, the article with the most details or the most
recent articles was chosen. CT studies without contrast
agent were excluded. Studies using sequential test combi-
nations (e.g., PET in patients selected on the basis of
abnormal US or CT image) were excluded because the
selection of patients on the basis of diagnostic test results
could have unpredictably modiﬁed the estimate of the
operative characteristics of the tests themselves (Sackett
and Haynes 2002).
Four reviewers, who had at least 3 years work experi-
ence in the special ﬁelds of US, CT, MRI, SMM or PET,
independently checked retrieved articles only in their own
ﬁelds. To minimize bias in the selection of studies, one
reviewer, who had more than 10 years work experience
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case of discordances, a consensus re-review between all
reviewers was performed.
Data extraction
Information extracted form each article included ﬁrst
author, study date, simple size, age of subjects, reference
standard, unit of analysis (patients or lesions), technical
characteristics of each imaging modality, and the number
of true positives, false positives, true negatives, and false
negatives. Data were extracted independently by the same
four observers. Data abstraction was not blinded with
regard to unnecessary information such as the authors, the
authors’ afﬁliation, the journal name or year of publication
(Berlin 1997). Disagreements were resolved in consensus.
Quality assessment
Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) criteria were used to assess the quality of every
article (Whiting et al. 2003). The following data were
extracted to perform accuracy analyses: (1) clinical char-
acteristics of the study sample described (age, sex, number
of patients enrolled, reason for performing particular
imaging modality); (2) patient selection (consecutive or
not); (3) study type (prospective, retrospective or
unknown); (4) independence of test interpretation (blinded
ornot);(5)veriﬁcationbias(nobias,limitedorconsiderable:
i.e., no bias means all patients or lesions were conﬁrmed
by histopathologic analysis; considerable veriﬁcation bias
means only a small number of patients or lesions were con-
ﬁrmedbyhistopathologicanalysis;otherswerereferredtoas
limited veriﬁcations bias).
The following features were also included: As to US,
type of probe, probe frequency (MHz) and type of scanning
were included. As to CT, the type of scanner (non-helical
or helical), section thickness, or use of contrast agent or not
were included. And as to MRI imaging, magnetic ﬁeld
strength, type of coil, use of contrast agent or not were
included. As to SMM, scanner, contrast agent, contrast
dose, collimator were included. As to FDG-PET, amount of
tracer, camera model, resolution, attenuation correction
and type of analysis (qualitative or quantitative or both)
were included. The numbers of TP, FN, false-positive (FP)
and true-negative (TN) results in the detection of recurrent
and/or metastatic breast cancer were extracted on a per-
patient or per-lesion.
Statistical analysis
A random effect model (Fleiss et al. 2003) was used for the
primary meta-analysis to obtain a summary estimate for
sensitivity and speciﬁcity with 95% conﬁdence intervals
(CI) of each non-invasive technique. We also calculated
summary receiver operating characteristic (SROC) curves
and the area under the curve (AUC). In a meta-analysis,
each separate study contributes an estimate of true-positive
rates (TPR) and false-positive rates (FPR). A graph is made
from the TPR and FPR points. The SROC curve is placed
over the points to form a smoothed curve which can be
achieved using a regression model proposed by Moses
et al. (1993). And then, we did Z test to ﬁnd whether the
sensitivity (SE), speciﬁcity (SP) and AUC of each modality
was signiﬁcantly different from others or not, if p\0.05
was considered as statistically signiﬁcant. All the statistics
(sensitivity, speciﬁcity, PPV, negative predictive value
(NPV), accuracy, SROC, AUC) refer to recurrence and
surveillance.
We tested the following items: threshold effects between
studies (Deeks 2001) using Spearman correlation coefﬁ-
cients q (the cutoff effect was considered present in the
case of a q value[0.4; Deville ´ et al. 2002); heterogeneity
using the likelihood ratio v
2 test (if p\0.05 was consid-
ered having apparent heterogeneity; Fleiss et al. 2003) and
I
2 index which is a measure of the percentage of total
variation across studies due to heterogeneity beyond
chance and takes values between 0 and 100%. Its values
over 50% indicate heterogeneity (Huedo-Medina et al.
2006). Publication bias was assessed by funnel plots. Since
data on US, CT, MRI or FDG-PET imaging were limited,
we did not perform subgroup analyses.
All of the statistical analyses were undertaken using
SAS statistical software version 8.2 (SAS Institute Inc.,
Cary, NC, USA) and Meta-DiSc (Version 1.4) (Zamora
et al. 2006). (Meta-DiSc, produced by Javier.zamora, is
freeware software to perform systematic review of studies
of evaluation of diagnostic and screening tests.)
Results
Literature search and study design characteristics
The computerized search yielded 1,017 primary studies, of
which 969 were excluded. The reasons for exclusion were
as follows: (a) the aim of the articles was not to reveal the
diagnostic value of US, CT, MRI, SMM, FDG-PET (with
or without CT) for identiﬁcation and characterization of
recurrent or metastatic breast cancer (n = 817); (b) the
reference standard was not used as histopathologic analysis
or close clinical and imaging follow-up for at least
6 months (n = 79); (c) data from the article that could be
used to construct or calculate TP, FP, TN and FN (n = 39);
(d) data from the article come from a combination of dif-
ferent imaging modalities that could not be differentiated
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123for assessment of single tests (n = 32); (e) article was
printed more than once, article with smaller population was
excluded (n = 2); (f) article that cannot be accessible
(n = 3); (g) data included less than 10 patients (n = 3). A
total of 43 studies (Yilmaz et al. 2007; Bongers et al. 2004;
Schmidt et al. 2008; Radan et al. 2006; Ternier et al. 2006;
Rissanen et al. 1993; Bruneton et al. 1986; Lee et al. 1993;
Gilles et al. 1993; Dehdashti et al. 1995; Melani et al. 1995;
Hagay et al. 1996; Winehouse et al. 1999; Rieber et al.
1997; Drew et al. 1998; Muu ¨ller et al. 1998; Moon et al.
1998; Cwikla et al. 1998; Hathaway et al. 1999; Qayyum
et al. 2000; Stuhrmann et al. 2000;B a ¨z et al. 2000; Eubank
et al. 2001, 2004; Kim et al. 2001; Belli et al. 2002;
Liu et al. 2002; Goerres et al. 2003;S u a ´rez et al. 2002;
Kamel et al. 2003; Gallowitsch et al. 2003; Siggelkow et al.
2003; De Cicco et al. 2004; Shin et al. 2005; Weir et al.
2005; Lamuraglia et al. 2005; Preda et al. 2006; Wolfort
et al. 2006; Piperkova et al. 2007; Rajkovaca et al. 2007;
Usmani et al. 2007; Haug et al. 2007; Riebe et al. 2007)
fulﬁlled all of the inclusion criteria and were considered for
the analysis (Table 1). 15 studies were prospective, 16
studies were retrospective, and the remaining was not
deﬁned. Patient selection was consecutive in 18 studies and
not deﬁned in 25. 11 studies took only histopathologic
analysis as reference standard, indicating a complete veri-
ﬁcation and lack of bias, while 10 studies showed limited
veriﬁcation bias and 22 studies still showed considerable
veriﬁcation bias. TP, FN, FP, TN results and some features
of each modality were shown in Tables 2, 3, 4, 5 and 6.
Publication bias, heterogeneity and cutoff effect
To assess a possible publication bias, scatter plots were
designed using the log diagnostic odd ratios (DORs) of
individual studies against their sample size. The funnel plot
of US, CT, MRI, SMM and PET was given in Fig. 1.I n
detail, the US, CT, MRI, SMM and PET showed marked
asymmetry (with small studies missing from the bottom
left quadrant, thus suggesting a publication bias). There
was heterogeneity for most non-invasive modalities except
SMM and PET, which conﬁrmed either by likelihood ratio
v
2 test or I
2 index (Table 7). There was no conclusive
evidence of a cutoff effect for US and PET to Spearman
correlation coefﬁcients (q\0.4). But a cutoff effect was
present for CT, MRI and SMM (q[0.4; Table 8).
Pooled sensitivity, pooled speciﬁcity and DORs
On the basis of a random effect model, pooled sensitivity,
pooled speciﬁcity and DOR of those non-invasive modal-
ities were shown in Table 9. Pooled sensitivity of MRI and
PET (with or without CT) was 0.9500 and 0.9530, respec-
tively, no statistical signiﬁcant difference was found
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123Table 2 TP, FP, FN, PN and other features of US (10 studies in all)
Author TP FP FN TN Reason to
perform US
Type
of probe
Probe
frequency
Contrast
agent
Contrast
dose
Image
interpretation
Criteria for the
presence of recurrent
or metastatic lesions
Yilmaz et al.
(2007)
9 2 1 15 Evaluated for
locoregional
recurrence
Linear 7.5 MHz No
contrast
No
contrast
NA Yes
Ternier et al.
(2006)
45 14 7 37 Suspicion of
recurrence
Real time 10–13 MHz No
contrast
No
contrast
Blind Yes
Rissanen
et al.
(1993)
50 5 5 9 Suspicion of
recurrence
Real time 7.5 MHz No
contrast
No
contrast
Blind Yes
Bruneton
et al.
(1986)
16 1 6 37 Follow-up of
breast cancer
NA 5.7 MHz No
contrast
No
contrast
NA Yes
Winehouse
et al.
(1999)
15 14 1 28 Suspicion of
recurrence
Pulsed
repetition
800–1,000 kHz Levovist 8 ml NA Yes
Stuhrmann
et al.
(2000)
16 6 1 5 Suspicion of
recurrence
Linear 5–10 MHz Levovist 4 g Not blind Yes
Ba ¨z et al.
(2000)
10 1 0 27 Suspicion of
recurrence
Linear 10–7.5 MHz Levovist 3.2 g Blind Yes
Shin et al.
(2005)
24 33 10 1,901 Suspicion of
recurrence
Linear 5–12 MHz No
contrast
No
contrast
Not blind Yes
Lamuraglia
et al.
(2005)
2 0 1 7 Suspicion of
recurrence
NA 9–14 MHz Sonovue 4.8 ml NA Yes
Riebe et al.
(2007)
10 5 1 11 Follow-up of
breast cancer
NA NA No
contrast
No
contrast
Blind Yes
Table 3 TP, FP, FN, PN and other features of CT (eight studies in all)
Author TP FP FN TN Reason to
perform CT
Technical Slice
thickness
(mm)
Contrast
agent
Contrast
dose
(ml)
Image
interpretation
Criteria for the
presence of recurrent
or metastatic lesions
Radan et al.
(2006)
14 9 6 8 TM evaluated Helical 4.25 Non-ionic
contrast
NA Not blind Yes
Ternier et al.
(2006)
47 5 5 46 Suspicion of
recurrence
Helical 3 Non-ionic
contrast
100 Blind Yes
Hagay et al.
(1996)
42 11 4 61 Suspicion of
recurrence
Helical 5 Iodinated
contrast
150 Blind Yes
Eubank et al.
(2001)
8 3 12 17 Suspicion of
recurrence
Spiral 5–7 Iodinated
contrast
150 Blinded Yes
Gallowitsch
et al. (2003)
28 9 5 15 Follow-up of
breast cancer
Spiral 3–5 Jopamiro 300 Blinded NA
Wolfort et al.
(2006)
9 0 4 7 Suspicion of
recurrence
NA NA NA NA NA NA
Piperkova
et al. (2007)
198 18 28 13 Restaging NA 3.75 Non-ionic
contrast
NA Blind Yes
Haug et al.
(2007)
23 2 2 7 With surgically
resected breast
cancer
NA 5 Non-ionic
contrast
120 Blind Yes
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123between MRI and PET (p[0.05). However, they had
highest pooled sensitivity, p\0.05, when compared with
US, CT and SMM. Pooled speciﬁcity of US and MRI was
0.962 and 0.929, respectively, no statistical signiﬁcant
difference was found between US and MRI (p[0.05).
However, they had highest pooled speciﬁcity, p\0.05,
when compared with CT, SMM and PET. The DOR
estimates for MRI and PET were 131.78 (95% CI 70.9310–
244.8100) and 106.88 (95% CI 68.1040–167.73), respec-
tively, and were signiﬁcantly higher than for US, CT and
SMM (p\0.05). The results were also shown in Table 9.
Summary ROC curves, AUC and the Q* index
Summary receiver operating characteristic analysis was
used to compare those non-invasive modalities. The AUC
of US, CT, MRI, SMM and PET (with or without CT) was
presented in Table 8. AUC of MRI and PET (with or
without CT) is 0.9718 and 0.9604, respectively; however,
no signiﬁcant difference was found between those two
modalities, p[0.05. Results of pairwise comparison
between each modality demonstrated that AUC of both
MRI and PET (with or without CT) was higher than that of
US or CT, p\0.05. AUC of SMM was 0.9386, no sta-
tistical signiﬁcance was found when compared with that of
MRI and PET (with or without CT), p[0.05. In terms of
its AUC, there was still no statistical signiﬁcance between
CT and US, p[0.05. The Q* index estimates for US, CT,
MRI, SMM and PET (with or without CT) were 0.8593,
0.7904, 0.9228, 0.8757 and 0.9051, respectively. Like
AUC, the Q* index estimates for MRI and PET were sig-
niﬁcantly higher than for US, CT and SMM, p\0.05.
And, they were similar for MRI and PET (Table 9; Fig 2).
Discussion
Soerjomataram et al. (2008) conducted a review to sum-
marize available knowledge on the determinants of sur-
vival 10 years or more after breast cancer diagnosis and
found that patients with recurrent metastasized or second
cancer generally exhibited lower long-term survival than
those without. Locoregional recurrences predominately
affect the breast, skin, the axillary and supraclavicular
nodes and the chest wall. Internal mammary (IM), medi-
astinal nodes, pleura and lung parenchyma are the most
common sites of intrathoracic recurrence after primary
surgical resection (Fisher et al. 2001; Hatteville et al.
2002). Extrathoracic recurrence often occurs in bone, liver
and brain. The correct identiﬁcation of local recurrences
and distant metastases at the time of suggestive symptoms
in the follow-up for breast cancer prompts clinical con-
sideration for administering different therapies (Nomura
et al. 1999; Wapnir et al. 2006). Thus, it is crucial for
patients with breast cancer to early detect recurrences or
metastases (Eubank et al. 2002; Kamby et al. 1988; Yang
Table 5 TP, FP, FN, PN and other features of SPECT (seven studies in all)
Author TP FP FN TN Reason to
perform
SPECT
Scanner Delay
image
(min)
Contrast
agent
Contrast
dose
(MBq)
Collimator Image
interpretation
Criteria
Bongers et al.
(2004)
30 3 1 21 Suspicion of
recurrence
A single head
gamma
camera
10 99mTc-
tetrofosmin
700 A high-
resolution
collimator
Blinded Yes
Lee et al.
(1993)
8 0 1 1 Suspicion of
recurrence
An Anger
camera
120 201Ti-
chloride
3 mCi A high-
resolution
collimator
Blinded Yes
Cwikla et al.
(1998)
8 3 1 23 Suspicion of
recurrence
NA NA 99mTc-
MIBI
NA A high-
resolution
collimator
Blinded Yes
Gallowitsch
et al. (2003)
97 7 11 20 Follow-up of
breast cancer
A double head
camera
180 99mTc-
MDP
740 A LEUHR
collimator
NA Yes
De Cicco
et al. (2004)
21 8 3 12 Suspicion of
recurrence
A single-head
gamma
camera
5 99mTc-
sestamibi
740 A high-
resolution
collimator
NA Yes
Rajkovaca
et al. (2007)
17 2 2 7 Suspicion of
recurrence
NA NA 99mTc-
sestamibi
NA A high-
resolution
collimator
NA Yes
Usmani et al.
(2007)
18 1 3 11 Suspicion of
recurrence
A double head
camera
5–10 99mTc-
MIBI
740–1,000 A high-
resolution
collimator
Blind Yes
1014 J Cancer Res Clin Oncol (2010) 136:1007–1022
123et al. 2007; Siggelkow et al. 2004). This meta-analysis
focused on evaluating the diagnostic ability of US, CT,
MRI, SMM and PET (interpreted with or without the use of
CT), which are the widely used non-invasive modalities for
the detection of recurrent and/or metastatic breast cancer.
Previous studies have discussed the diagnosis ability of
US in detecting recurrent and/or metastatic breast cancer.
Lamuraglia et al. (2005) determined the efﬁcacy of
Doppler US with contrast agent (DUPC) in local recurrent
breast cancer, revealed a SE of 67% and a SP of 100%.
Eubank et al. (2001) evaluated the beneﬁt of echo-contrast-
enhanced Doppler sonography the differentiation of benign
versus malignant breast lesions in 38 patients who had
surgical removal of a malignant breast mass. The baseline
ultrasound examination showed an SE of 50% and an SP of
86%, after contrast enhancement the ultrasound ﬁndings
Table 6 TP, FP, FN, PN and other features of PET (21 studies in all)
Author TP FP FN TN Reason to
perform PET
Fast
hour
(h)
FDG-dose Range Method Image
interpretation
Criteria
Schmidt
et al.
(2008)
170 8 16 69 Suspicion of
recurrence
[6 202–378 MBq Whole-body format SUV Blind Yes
Radan et al.
(2006)
151 5 2 13 TM evaluated [4 370–666 MBq Whole-body format SUV Not blind Yes
Dehdashti
et al.
(1995)
17 0 2 2 Suspicion of
recurrence
[4 370 MBq Whole-body format SUV Blinded Yes
Moon et al.
(1998)
27 6 2 22 Suspicion of
recurrence
[6 370–555 MBq A Whole-body mode Visualization Not blinded Yes
Hathaway
et al.
(1999)
9 0 0 1 Suspicion of
recurrence
[4 260–370 MBq Whole-body format SUV Blinded Yes
Kim et al.
(2001)
46 2 2 11 Suspicion of
recurrence
[12 370–555 MBq From the buttom to
cerebellum
Visualization
SUV
NA Yes
Liu et al.
(2002)
35 2 3 10 Suspicion of
recurrence
[4 370 MBq From the bladder level
to the head
Visualization Not blind Yes
Goerres
et al.
(2003)
14 5 0 13 Suspicion of
recurrence
[4 386 MBq From the pelvic to the
head
SUV Blinded Yes
Sua ´rez et al.
(2002)
24 3 2 9 TM evaluated [4 NA Whole-body format NA Blinded NA
Kamel et al.
(2003)
85 5 3 25 Suspicion of
recurrence
[4 300–400 MBq From head to pelvic
ﬂoor
SUV Blinded Yes
Gallowitsch
et al.
(2003)
33 5 1 23 Follow-up of
breast cancer
[12 200 MBq From the base of the
skull to the thigh
Visualization Blinded Yes
Siggelkow
et al.
(2003)
31 3 4 35 TM evaluated or
suspicion of
recurrence
[4 NA Whole-body format Visualization Blinded Yes
Eubank
et al.
(2004)
16 4 1 40 Suspicion of
recurrence
[4 244–400 MBq From the neck to the
buttom of liver
SUV Not blind Yes
Weir et al.
(2005)
8 2 1 16 Suspicion of
recurrence
[6 555 MBq Whole-body format NA NA NA
Wolfort
et al.
(2006)
13 0 1 7 Suspicion of
recurrence
NA NA NA NA NA NA
Piperkova
et al.
(2007)
221 2 5 29 Restaging [4 10–15 mCi From the mid-thigh
to the base of
the skull
SUV Blind Yes
Haug et al.
(2007)
24 1 1 8 With surgically
resected breast
cancer
[6 200 MBq From the base of the
skull to the middle of
the femora
SUV Blind Yes
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123demonstrated an SE of 100% and an SP of 96%. In con-
clusion of their ﬁndings, it suggests that contrast-enhanced
sonography aids in the differentiation of local recurrence
from benign scar lesions. Therefore, US may be most
useful when abnormal, but normal values cannot exclude
the presence of active disease.
CT imaging, by virtue of its cross-sectional display, is
widely used in recent years. However, reports in the liter-
ature differ with regard to diagnostic accuracy of CT
imaging in detecting recurrent and/or metastatic breast
cancer, ranging from 40 to 92% and from 41 to 100% for
SE and SP, respectively (Radan et al. 2006; Ternier et al.
2006; Winehouse et al. 1999;B a ¨z et al. 2000; Gallowitsch
et al. 2003; Piperkova et al. 2007; Riebe et al. 2007;
Armington et al. 1987). Recently, CT has been the main
modality used to evaluate mediastinal nodes in oncology,
but as this technique uses size as the main criterion to
assess nodal status, it is limited by poor SE. Landheer et al.
(2005) also found that metastatic lymph nodes are often not
identiﬁed by CT, and those smaller than 1 cm are often
described as non-pathological. Due to their small size and
anatomical position, it is difﬁcult to conﬁrm a pathological
diagnosis. Moskovic et al. (1992) found that the detection
rate of CT of breast cancer recurrence in patients without a
palpable axillary mass is extremely low and they suggested
that this technique unjustiﬁed screening for clinically
occult axillary disease in patients with arm symptoms
following axillary surgery or radiation therapy for breast
cancer. Similarly, Armington et al. (1987) demonstrated
that 11 of 30 patients with axillary and supraclavicular
Fig. 1 Funnel plots of US, CT,
MRI, SPECT and PET
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123lesions were missed because of inadequate visualization of
the axillary apex with CT imaging. To date, early detection
of metastases by repeated conventional imaging tests (CT,
ultrasound, and bone scintigraphy) has not been shown to
be of beneﬁt over routine follow-up in terms of patient
survival (McLoud et al. 1992; Webb et al. 1991).
Previous studies have demonstrated that the contrast-
enhanced MRI imaging of the breast has been a sensitive
modality for the detection of breast tumor recurrence, with
a SE of nearly 100%, and this has become one of the most
common indications for the examination (Kneeland et al.
1987; de Verdier et al. 1993; Bilbey et al. 1994; The
GIVIO Investigators 1994). Preda et al. (2006) investigated
93 consecutive patients with breast cancer; the SE, SP, and
NPV of MRI for the diagnoses of recurrent breast cancer
were 93.8, 90, and 98.8%, respectively. The NPV of MRI,
which indicates a very low likelihood of new malignancy if
MRI deﬁnes the lesion as benign, is impressingly high.
And, Preda suggests that lesions graded by MRI as Fisher
I–II (BI-RADS I–II) can be safely monitored with the
usual yearly follow-up. A repeat MRI examination after
6 months is recommended for lesions graded as Fischer
III (BI-RADS III), if there is no clinical suspicion of
recurrence before 6 months. For lesions graded higher
than Fischer IV (BI-RADS IV), further cytological or
histological evaluation is mandatory. This result is in line
with previous result provided by Heywang-Ko ¨brunner
(et al. 1993), with a NPV of 100%. Schmidt et al. (2008)
compared the performance in recurrent breast cancer
patients using FDG-PET/CT and whole-body MRI and
found that whole-body MRI showed a higher diagnostic
accuracy of 94 versus 90% for FDG-PET/CT. In our
study, we synthesized the currently available information
of MRI in detecting recurrent and/or metastatic breast
cancer, and found that the pooled sensitivity, pooled
speciﬁcity and AUC are 0.9500, 0.929 and 0.9718,
respectively. On the basis of current evidences, the
overall diagnostic ability of MRI and PET was similar;
however, MRI had the advantage that it had excellent
contrast in soft tissue and parenchymal structures and the
larger anatomical coverage compared to PET/CT (skull
base to proximal femurs).
SMM is the method by which breast pathology is
identiﬁed using a radiopharmaceutical. The agent used can
be tumor speciﬁc such as 99m Tc-sestamibi (99mTc-MIBI)
or a non-speciﬁc tracer such as 99mTc-methylene diphos-
phonate (99mTc-MDP) and Thallium-201. Several clinical
studies have reported that 99mTc-MIBI SMM is accurate
in differentiating palpable breast lesions, and the utility of
the technique has been emphasized in decreasing the
number of breast biopsies (Landheer et al. 2005; Kao et al.
1994). Although multi-center trials had been done, SMM
has not been widely adopted to resolve cases that
are equivocal by mammography (Khalkhali et al. 1995;
Tolmos et al. 1998). The major problem is the lower SE of
SMM for non-palpable tumor. Tiling et al. (1998) made a
meta-analysis and showed that SMM may be useful
Table 7 Test for heterogeneity and threshold effect in the meta-
analysis
Likelihood ratio I
2 index (%)
v
2 p
Sensitivity
US 15.48 0.079 41.9
CT 31.51 0.000 77.8
MRI 22.13 0.014 54.8
SPECT 2.66 0.85 0.0
PET 23.24 0.108 31.1
Speciﬁcity
US 159.69 0.000 94.4
CT 39.99 0.000 82.5
MRI 11.38 0.328 12.2
SPECT 8.72 0.19 31.2
PET 15.58 0.483 0
Table 8 AUC and Q* index and q value for US, CT, MRI, SPECT
and PET
Modality AUC Q* index q value
US 0.9251 0.8593 0.0890
CT 0.8596 0.7904 0.6510
MRI 0.9718 0.9228 0.9470
SMM 0.9386 0.8757 0.9390
PET 0.9604 0.9051 0.1390
Table 9 Summary estimates of sensitivity, speciﬁcity, and diagnostic odds ratio (DOR) for US, CT, MRI, SPECT and PET
Modality Sensitivity (%) Speciﬁcity (%) Diagnostic OR
US 0.8570 (0.8040–0.8990) 0.9620 (0.9540–0.9700) 40.9280 (18.2940–91.5670)
CT 0.8480 (0.8110–0.8810) 0.7530 (0.6920–0.8070) 13.6200 (4.8870–37.9540)
MRI 0.9500 (0.9230–0.9700) 0.9290 (0.9020–0.9500) 131.7800 (70.9310–244.8100)
SMM 0.9000 (0.8530–0.9370) 0.7980 (0.7150–0.8660) 29.4190 (14.8800 –58.1640)
PET 0.9530 (0.9370–0.9650) 0.8630 (0.8240–0.8950) 106.8800 (68.1040–167.7300)
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123in recurrent breast cancer because post-surgical or
post-radiotherapy changes made anatomical methods of
imaging of limited use. But due to the number of patients
studied was rather small, SMM cannot be recommended
for detection of recurrent and/or metastatic breast cancer.
PET with radiolabeled glucose analog FDG is a method
that is based on the increased glucose metabolism of
malignant tumors. It can reveal the functional information
that even the most exquisitely detailed anatomic image
cannot provide. FDG-PET seems to have reasonable sen-
sitivity and speciﬁcity in the detection of recurrent and
metastatic breast cancer, particularly in the subset of
patients presenting with elevated tumor markers (Aide
et al. 2007). Sua ´rez et al. (2002) reported that patients with
CA153 blood levels above 60 U/ml were always associated
with positive PET, while CA153 blood levels below
50 U/ml were always associated with negative one. Liu
et al. (2002) got the similar results, the diagnostic SE and
accuracy of FDG-PET in patients with suspected recurrent
breast cancer and asymptomatically elevated tumor mark-
ers were 96 and 90%. When compared to CT and MRI,
PET was shown to be superior in the detection of medi-
astinal and IM node metastases (Eubank et al. 2001;
Goerres et al. 2003). As for bone scintigraphy, PET had
also been shown to be superior in detecting bone metas-
tases (Kao et al. 2000).
PET–CT is a full-ring-detector clinical PET scanner
combined with a multi-detector row helical CT scanner,
which allows contemporaneous and co-registered acqui-
sition of both PET and CT images (Fueger et al. 2005). In
a retrospective review of 75 patients with suspected
breast cancer, Tatsumi et al. (2006) compared perfor-
mance of PET and PET/CT. PET/CT resulted in improved
diagnostic conﬁdence compared with PET in 60% of
patients and in 55% of regions. Another two publications
(Radan et al. 2006; Pecking et al. 2001) drew similar
results; the use of PET/CT technology indicated only a
marginal improvement in diagnostic accuracy, reporting
SE, SP and accuracy rates of 90, 71, 83%, and 94, 84,
99%, respectively. Most importantly, several studies
demonstrated that FDG-PET/CT had an impact on the
management of 51–69% of patients (Radan et al. 2006;
Eubank et al. 2004).
To our knowledge, this meta-analysis was the ﬁrst
report that assessed and compared summary estimates of
overall diagnostic ability for those non-invasive methods
that were currently used for detecting recurrent and/or
metastatic breast cancer. In this clinical context, if those
methods were compared with each other, the results of
our meta-analysis demonstrated that US had the highest
SP and PET had the highest SE. The AUC of MRI and
PET, whether interpreted with or without the use of CT,
was higher than that of US or CT, but there was no
statistically signiﬁcant difference when PET or MRI was
compared with SMM. Because of the highest SE, an
abnormal US image was always a strong indication of
recurrent tumor; however, US had disadvantages in cases
of fat necrosis and structural distortion after surgery and
furthermore its results do not usually alter the manage-
ment plan in terms of biopsy or follow-up determined on
the basis of physical and/or mammographic ﬁndings
(Bruneton et al. 1986). Therefore, additional imaging
information of the recurrent and/or metastatic foci was
necessary to a highly suspected patient with an indeter-
minate US. In our meta-analysis, both MRI and PET had
highest SE, which resulted in higher cancer detection
rate. Regarding that PETs’ high expense and modest
whole-body radiation exposure, PET was not suited for
screening purposes in breast cancer. Therefore, MRI
should be the next diagnostic step in patients with an
indeterminate or low probability of malignancy. Since
that whole-body mets with MRI is impractical in most
circumstances, PET had its own advantages in whole-
body surveillance for mets. When MRI shows an inde-
terminate or benign lesion or MRI was not applicable
(e.g., pacemaker), FDG-PET could be performed in
addition. Furthermore, a lesion that was indeterminate or
benign on MRI and negative on PET indicated a very low
probability of malignancy. In conclusion, MRI seemed to
be a more useful supplement to current surveillance
techniques to assess patients with suspected recurrent
and/or metastatic breast cancer.
To be sure, our study had some drawbacks. Firstly, the
effect of characteristics of the patients could not be
examined due to lack of data. Secondly, the reference
standard used in this systematic review ranged from
histopathologic analysis to follow-up. Thirdly, most
results showed heterogeneity, suggesting the needs for
high-quality prospective studies and multi-center trials.
Fourthly, the possibility of publications bias occurred in
our meta-analysis. It was possible that our pooled esti-
mates were too optimistic, as studies with favorable
results were more likely to be submitted and published.
Finally, further cost-effectiveness analysis should be
conducted regards to the surveillance techniques in the
breast cancer.
Conclusion
In conclusion, MRI seemed to be a more useful supplement
to current surveillance techniques to assess patients with
suspected recurrent and/or metastatic breast cancer. If MRI
shows an indeterminate or benign lesion or MRI was not
applicable (e.g., pacemaker), FDG-PET could be per-
formed in addition.
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